Following the recent BRAVE-AA trials Olumiant (baricitinib) has become the first USFDA approved systemic treatment (i.e. treats the entire body rather than a specific location) for Alopecia Areata.
About the new Drug (Baricitinib)
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib may interrupt cytokine signalling implicated in the pathogenesis of alopecia areata.
See the full results of the two randomized, double-blind, placebo-controlled BRAVE-AA trials.
The FDA commented on the announcement:
“Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.”
For full details visit fda.gov